Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 18/20 | 0.57 |
| ▸ | FLT1 | P17948 | 9/20 | 0.57 |
| ▸ | PDGFRB | P09619 | 8/20 | 0.57 |
| ▸ | KIT | P10721 | 7/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1929579 | 0.80 | KDR (0.52) | KDRFLT1PDGFRBKITMEN1 | |
| SCHEMBL6503289 | 0.74 | KDR (0.70) | KDRFLT1PDGFRBKITMEN1 | |
| SCHEMBL905633 | 0.73 | KDR (1.00) | KDRFLT1PDGFRBKITMEN1 | |
| SCHEMBL6504661 | 0.72 | KDR (0.49) | KDRFLT1PDGFRBKITMEN1 | |
| SCHEMBL31583016 | 0.72 | LOXL2 (0.62) | — | |
| SCHEMBL14486857 | 0.72 | LOXL2 (0.62) | — | |
| SCHEMBL26907246 | 0.72 | LOX (0.47) | KDRFLT1PDGFRBKITMEN1 | |
| SCHEMBL905704 | 0.71 | KDR (1.00) | KDRFLT1PDGFRBKITMEN1 | |
| SCHEMBL13773458 | 0.70 | KDR (0.59) | KDRFLT1PDGFRBKIT | |
| SCHEMBL6473753 | 0.69 | KDR (0.53) | KDRFLT1PDGFRBKITMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7399761-B2 | Phthalazine derivatives with angiogenesis inhibiting activity | NOVARTIS AG (CH) | 2008-07-15 | — | — | US | disclosed |
| US-20040180899-A1 | Phthalazine derivatives with angiogenesis inhibiting activity | NOVARTIS AG (CH) | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180899-A1 | Phthalazine derivatives with angiogenesis inhibiting activity | VEGFA, NR5A1, PGF | KDR 13/4885FLT1 5/4885PDGFRB 621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.